The Role of Noncontrast Computed Tomography Markers in Predicting the Clinical Outcome of Cerebral Hemorrhage

July 30, 2024 updated by: Jin Hu

The goal of this observational study is to To investigate the ability of Noncontrast Computed Tomography to predict clinical prognosis in Intracerebral Hemorrhage.

The main question it aims to answer is:How to judge the prognosis of patients with cerebral hemorrhage by CT image reading at admission.

Study Overview

Status

Not yet recruiting

Conditions

Study Type

Observational

Enrollment (Estimated)

1000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with cerebral hemorrhage who met the criteria and were admitted continuously within the time period

Description

Inclusion Criteria:

  1. Age≥18 years
  2. had completed a CT examination within 24 h of disease onset;
  3. had a hemorrhage that was located in the brain parenchyma, including the basal ganglia, thalamus,brain lobes, brainstem, and cerebellum.

Exclusion Criteria:

  1. had secondary ICH caused by brain trauma,cerebrovascular malformations, aneurysms, and tumors;
  2. had ischemic cerebral infarction hemorrhagic transformation;
  3. had undergone surgical treatment (e.g.hematoma removal or puncture drainage) before the CT examination;
  4. had images of poor quality that could notbe accurately evaluated;
  5. had a hematoma withborders that could not be delineated, thus precluding delineation of the region of interest (ROI).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
The prognosis of cerebral hemorrhage is good at 90 days
The prognosis of cerebral hemorrhage is poor at 90 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The prognosis of cerebral hemorrhage at 90 days
Time Frame: 90 days
The Modified Rankin Scale was used to evaluate the prognosis of the patients, and MRS Score >2 indicated poor prognosis
90 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Jin Hu

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

August 1, 2024

Primary Completion (Estimated)

August 31, 2024

Study Completion (Estimated)

August 31, 2024

Study Registration Dates

First Submitted

July 30, 2024

First Submitted That Met QC Criteria

July 30, 2024

First Posted (Actual)

August 2, 2024

Study Record Updates

Last Update Posted (Actual)

August 2, 2024

Last Update Submitted That Met QC Criteria

July 30, 2024

Last Verified

July 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • FDHS2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intracerebral Hemorrhage

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe